One of the major challenges in the treatment of cancer is the large variety of oncogenic alterations within the cancer genome affecting many different cellular processes. As such, effective therapy will likely be based on the specific genetic alterations present in each patient's tumor rather than a single generalized therapy regimen. I recently discovered frequent inactivating mutations of genes including STAG2 that encode the multi- protein cohesin complex in several tumors including glioblastoma, urothelial carcinoma, Ewing sarcoma, and acute myeloid leukemia (AML), which define molecular subgroups of these tumors with distinct clinical outcomes. The cohesin complex is responsible for sister chromatid cohesion following DNA replication and helps ensure faithful chromosome segregation during mitosis, but has also been implicated in additional cellular processes such as regulation of chromatin architecture and gene transcription. My studies in glioblastoma demonstrated that STAG2 mutations were a direct cause of chromosomal instability and aneuploidy; however, cohesin gene alterations in urothelial carcinoma and AML have been identified primarily in near-diploid tumors, suggesting alternative mechanisms by which cohesin inactivation drives oncogenesis. Using a newly generated conditional STAG2 knockout mouse and previously generated isogenic sets of STAG2 proficient and deficient cancer cell lines, I have designed a series of experiments to determine the function of STAG2 during mouse development and tumorigenesis and identify therapeutic methods to selectively target cancer cells harboring cohesin gene mutations. In the first aim, I will determine the impact on murine development of inducing STAG2 knockout starting in embryogenesis using both histologic and cellular characterization. In the second aim, I will determine the function of STAG2 in urothelial carcinogenesis and gliomagenesis by inducing specific knockout of STAG2 within the epithelium of the urinary tract and glial cells of the central nervous system. The proposed studies will prove if STAG2 is a bona fide tumor suppressor gene, identify cooperating genetic alterations, and determine whether chromosomal instability is a driving oncogenic mechanism. In the third aim, I will determine possible alternative mechanisms by which STAG2 inactivation contributes to tumor development. I will perform experiments to assess the hypothesis that cohesin localizes to regulatory regions of genes that control cellular differentiation and that STAG2 inactivation disrupts cohesin- mediated regulation of these genes controlling differentiation. In the final aim,I will use isogenic sets of STAG2 proficient and deficient cells to determine the role of cohesin in DNA damage repair and the response to radiation and specific DNA damaging agents, as well as perform a CRISPRi-based negative selection screen in order to identify gene products that are required (i.e. synthetically lethal) in the presence STAG2 inactivation. Together, these experiments will determine the function of STAG2 in mouse development and tumorigenesis and identify therapeutic vulnerabilities in the many cancers harboring cohesin gene alterations.

Public Health Relevance

Proper chromatin architecture within the cell nucleus and segregation of chromosomes into two daughter cells during cell division is maintained by cohesin, a multi-protein complex present in all cells from yeast to humans whose dysfunction has been hypothesized to drive cancer formation and progression. I have recently discovered genetic inactivation of a key component of the cohesin complex (STAG2) in a variety of tumors including the brain cancer glioblastoma, the bladder cancer urothelial carcinoma, the bone tumor Ewing sarcoma, and the blood cancer acute myeloid leukemia. The proposed research seeks to define the mechanisms by which these cohesin gene alterations result in tumor formation and to identify therapeutic mechanisms to selectively kill cancer cells harboring cohesin alterations.

Agency
National Institute of Health (NIH)
Institute
Office of The Director, National Institutes of Health (OD)
Type
Early Independence Award (DP5)
Project #
1DP5OD021403-01
Application #
9002395
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Basavappa, Ravi
Project Start
2015-09-19
Project End
2020-08-31
Budget Start
2015-09-19
Budget End
2016-08-31
Support Year
1
Fiscal Year
2015
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Pathology
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118
North, Jeffrey P; Golovato, Justin; Vaske, Charles J et al. (2018) Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma. Nat Commun 9:1894
Wood, Matthew D; Tihan, Tarik; Perry, Arie et al. (2018) Multimodal molecular analysis of astroblastoma enables reclassification of most cases into more specific molecular entities. Brain Pathol 28:192-202
Lee, Julieann; Putnam, Angelica R; Chesier, Samuel H et al. (2018) Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts. Acta Neuropathol Commun 6:95
Goode, Benjamin; Joseph, Nancy M; Stevers, Meredith et al. (2018) Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation. Mod Pathol 31:660-673
Hayes, Josie; Yu, Yao; Jalbert, Llewellyn E et al. (2018) Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. Neuro Oncol 20:632-641
Lelo, Alana; Prip, Frederik; Harris, Brent T et al. (2018) STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer. Clin Cancer Res 24:4145-4153
Ding, Siyuan; Diep, Jonathan; Feng, Ningguo et al. (2018) STAG2 deficiency induces interferon responses via cGAS-STING pathway and restricts virus infection. Nat Commun 9:1485
Iorgulescu, J Bryan; Van Ziffle, Jessica; Stevers, Meredith et al. (2018) Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. Acta Neuropathol 135:635-638
Pekmezci, Melike; Villanueva-Meyer, Javier E; Goode, Benjamin et al. (2018) The genetic landscape of ganglioglioma. Acta Neuropathol Commun 6:47
Pekmezci, Melike; Stevers, Meredith; Phillips, Joanna J et al. (2018) Multinodular and vacuolating neuronal tumor of the cerebrum is a clonal neoplasm defined by genetic alterations that activate the MAP kinase signaling pathway. Acta Neuropathol 135:485-488

Showing the most recent 10 out of 26 publications